Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 31 to 40 of 43

TitleTypeExpected publication date
Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]Technology appraisal guidanceTBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]Technology appraisal guidanceTBC
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]Technology appraisal guidanceTBC
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]Technology appraisal guidance
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]Technology appraisal guidance
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]Technology appraisal guidanceTBC
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]Technology appraisal guidance
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]Technology appraisal guidanceTBC
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]Technology appraisal guidanceTBC
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All